An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.

about

Cancer immunotherapy: are we there yet?

P2860

Q39297560-D4460F67-6DE6-4F3B-B5A2-55E435924DF4

P2860

An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.

Item

http://www.wikidata.org/entity/Q38068207

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.

@en

type

Item

label

An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.

@en

prefLabel

An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.

@en

P1476

An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.

@en

P2093

Sanjiv S Agarwala

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.

Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

P304

1449-1459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1586/ERA.12.120

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23249109

http://www.w3.org/2001/XMLSchema#string

An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.

about

P2860

P2860

An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698